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1. ABSTRACT 
Systemic sclerosis (SSc) is characterized by chronic inﬂammation and ﬁbrosis. 
N-Formyl peptide receptors (FPRs) are chemotactic receptors involved in 
inﬂammation. Three FPRs have been identiﬁed: FPR1, FPR2, and FPR3.  
We have examined, by RT-PCR, Western blot and immunohistochemistry, FPRs 
expression in skin ﬁbroblasts from normal subjects and SSc patients, showing an 
increased expression in SSc ﬁbroblasts.  
Several functions of FPRs occur through the interaction with the chemotactic 
domain (residues 
88
SRSRY
92
) of the urokinase-type plasminogen activator 
receptor (uPAR). Western blot and immunohistochemistry analysis also showed 
an increased expression in SSc ﬁbroblasts of a cleaved uPAR form exposing the 
SRSRY sequence at its N-terminus (DIIDIII-uPAR88–92).  
We demonstrated that FPRs stimulation promoted radical oxygen species (ROS) 
generation in normal and SSc ﬁbroblasts. Upon stimulation, ROS production 
was due to FPRs interaction with uPAR and to 1 integrin engagement. FPRs 
cross-talk with uPAR and integrins led to Rac1 and ERKs activation. Rac1 is a 
cytosolic component of the NADPH oxidase system. Active GTP-Rac1 binds to 
p67
phox
 that translocates to the membrane and associates with the catalytic 
gp91
phox
. FPRs stimulation promoted gp91
phox
 and p67
phox
 expression as well the 
direct interaction between GTP-Rac1 and p67
phox
 in fibroblast cells.  
Finally, we were able to show that C37, a new small molecule inhibiting the 
structural and functional interaction between FPRs and uPAR, and Selumetinib, 
a clinically approved MAPKK/ERK inhibitor, blocked FPRs-mediated ROS 
production in fibroblasts, thus suggesting new therapeutic strategies for the 
treatment of fibrosis in SSc. 
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2. INTRODUCTION 
2.1 Systemic Sclerosis: general aspects 
Systemic Sclerosis (SSc), also known as Scleroderma, is a chronic multisystem 
autoimmune disease characterized by excessive deposition of collagen and other 
connective tissue macromolecules in the skin and in multiple internal organs, 
severe alteration in the microvasculature and immunologic abnormalities. It is a 
rare but severe disorder characterized by clinical heterogeneity, an unpredictable 
course, high mortality and resistance to therapy (1, 2). Clinical forms range from 
limited skin involvement with minimal systemic alterations (lcSSc) to forms with 
diffuse skin sclerosis and severe internal organ disease (dcSSc) (3). 
The studies of the prevalence and incidence of SSc indicate a prevalence ranging 
from 50 to 300 cases per 1 million persons and an incidence ranging from 2.3 to 
22.8 cases per 1 million persons per year. Woman (age range between 30 and 50 
years) are at much higher risk for scleroderma then men, with a ratio ranging from 
3:1 to 14:1. The survival rate is between 34 and 76% and is strictly related to the 
level of internal organs involvement (4). 
 
2.2 Pathogenesis of Systemic Sclerosis 
The pathogenesis of SSc is extremely complex and remains not fully understood. 
At present, no single unifying hypothesis explains all aspects of its pathogenesis. 
However, fundamental abnormalities in at least 3 types of cells are involved in the 
development of the clinical and pathologic manifestations of the disease: 1) 
fibroblasts; 2) endothelial cells; 3) innate immune cells, particularly T and B 
lymphocytes (Fig. 1).  
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The functional alterations in these cells determine progressive cutaneous and 
visceral fibrosis, vascular lumen obliteration, immunologic dysregulation, which 
include the production of numerous autoantibodies, the chronic mononuclear-cell 
infiltration of affected tissues, the dysregulation of lymphokine and growth factor 
production (2). 
At present, it is not yet clear which alteration is of primary importance in SSc and 
despite a number of studies that examined several aspects of its intricate picture, 
the mechanisms involved are still largely unknown. During the past decade, 
considerable attention has been paid to the origin of myofibroblast, the 
mesenchymal cell type most responsible for the excessive matrix production and 
deposition in tissue and vessel wall, found in ﬁbrotic disorders and 
ﬁbroproliferative vasculopathies (5). However, in SSc, the origin of 
myoﬁbroblasts has not been completely elucidated. In ﬁbrotic diseases, 
myoﬁbroblasts may derive from at least three sources: 1) expansion and activation 
of resident tissue ﬁbroblasts; 2) transition of epithelial cells into mesenchymal 
cells, a process known as epithelial–mesenchymal transition (EMT); and 3) tissue 
migration of bone marrow–derived circulating ﬁbrocytes (6).  
Under normal circumstances, the ﬁbroblast repair program is self limited, but 
pathological ﬁbrotic responses are characterized by sustained and ampliﬁed 
ﬁbroblast activation (5) (Fig. 2). In SSc, uncontrolled fibroblasts activation, 
accumulation of myofibroblasts in affected tissues and their biosynthetic functions 
are crucial determinants of the extent and rate of ﬁbrosis and inﬂuence 
significantly the clinical course of the disease as well as the response to therapy, 
thus dictating the prognosis and the overall mortality (5).  
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Fibroblasts acquiring a myoﬁbroblast phenotype express typical mesenchymal 
markers, such as -smooth muscle actin (-SMA), vimentin, and type I collagen. 
Besides the acquisition of an activated proﬁbrogenic phenotype, these cells also 
become motile and capable of migrating into surrounding tissues (5, 6). 
Recently, endothelial mesenchymal transition (EndoMT), a newly recognized type 
of cellular trans-differentiation, has emerged as another possible source of tissue 
myoﬁbroblasts, deeply involved in the pathogenesis of ﬁbrotic disease (7).  
 
2.3 Oxidative stress in Systemic Sclerosis 
Several years ago, the pathogenesis of SSc was linked to the presence of a large 
excess of reactive oxygen species (ROS). This hypothesis, over the years, has 
been supported by numerous reports which documented the presence of an 
abnormal redox state in SSc patients and several other fibrotic disorders (8, 9). 
Although the role of ROS-induced oxidative stress in the pathogenesis of SSc has 
not been studied as extensively, it has been shown that ROS contribute to the 
persistent ﬁbrotic phenotype of SSc ﬁbroblasts (10) and that antioxidants, such as 
epigallocatechin-3gallate, can reduce extracellular component matrix (ECM) 
production, function, and activity of dermal ﬁbroblasts from SSc patients (11). 
Among the major source of ROS, nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases have been demonstrated to play a fundamental role in ROS 
production and in the redox signaling (12). The NADPH oxidase (also called 
Nox) complex was originally identified in phagocytic leukocytes as an enzymatic 
defense system against infections required for the oxidative burst-dependent 
microbial killing. It is composed of membrane-associated and cytosolic 
components, which assembly to form the active Nox enzymatic complex in 
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response to appropriate stimuli. Specifically, this complex consists of membrane-
associated cytochrome b558, comprising the catalytic gp91
phox
 (also known as 
Nox2) and regulatory p22
phox
 subunits, and four cytosolic regulatory components, 
including p40
phox
, p47
phox
, p67
phox
 and the small GTPase Rac1. Upon stimulation, 
p47
phox
 is phosphorylated and forms a complex with the other cytosolic subunits. 
This complex migrates to the cell membrane where it combines with cytochrome 
b558 to constitute the active enzyme which transfers electrons from a substrate to 
O2, generating O2
-
 (13). 
Subsequently, NADPH oxidase complexes were also found in nonphagocytic 
cells, where several isoforms of the catalytic Nox2 protein were identified, 
including Nox1, Nox3, Nox4, Nox5, Duox1 and Duox2. The expression of the 
catalytic subunits varies among different cell types, and it has become clear that 
generated ROS modulate a variety of cellular functions, including proliferation, 
migration, cell contraction, growth, apoptosis, and senescence (14).  
It is known that processes such as inflammation, ischemia or hypoxia are 
characterized by a significant increase in ROS production through the activation 
of NADPH oxidase. In fact, molecules such as VEGF, PDGF, TGF-β, angiotensin 
II and thrombin, all significantly higher in SSc patients than in controls, are able 
to stimulate the various subclasses of Nox family present in vascular smooth 
muscle cells and fibroblasts (15). In these cells, the redox state may play a 
significant role in the progression of fibrosis through an auto-amplification circuit 
linking ROS, Ras and ERK 1/2 which in turn amplifies and maintains the 
autocrine loop made up by cytokines, growth factors and their cognate receptors. 
For this reason, inappropriate NADPH oxidase activation seem to play a 
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fundamental role in determining events such as pulmonary hypertension, renal 
crisis and skin fibrosis (12).  
The evidence of platelet derived growth factor receptor (PDGFR) agonistic 
autoantibodies in the sera of SSc patients and the finding of their ability in 
inducing ROS from monocytes and fibroblasts has provided a novel clue to the 
pathogenesis of the disease (16).  
Thus, the study of the molecular mechanisms of ROS generation and involvement 
in the pathogenesis of SSc may lead to the development of novel treatments 
potentially transferable to the therapy of scleroderma patients.  
 
2.4 The N-formyl peptide receptors (FPRs) 
Leukocytes infiltration at sites of inflammation and infection is dependent on the 
presence of a gradient of chemotactic factors or chemoattractants. Synthetic N-
formyl-methionyl-leucyl-phenylalanine (fMLF) was one of the first identified 
highly potent chemoattractants for leukocytes. In 1976, a high-affinity binding site 
was found on the cell surface of neutrophils for the prototypic fMLF, and was 
biochemically defined formyl peptide receptor (FPR) (17). Subsequently, using a 
FPR cDNA probe, two other human genes were isolated by hybridization and 
called FPRL1 (formyl peptide receptor like 1) and FPRL2 (formyl peptide 
receptor like 2), which were shown to cluster with FPR on human chromosome 
19q13.3–19q13.4. FPRL1, also termed lipoxin A4 (LXA4) receptor ALX, is a 
low-affinity receptor for fMLF, based on its in vitro activation by high 
concentrations (μM) of fMLF. FPRL2 does not bind or respond to N-formyl 
peptides, but instead shares some non-formylated chemotactic peptide ligands 
with FPRL1 (18).  
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In 2009, the International Union of Basic and Clinical Pharmacology named the 
formyl peptide receptor subtypes FPR, FPRL1, and FPRL2 to FPR1, FPR2/ALX, 
and FPR3, respectively (19). 
FPRs belong to a class of G-protein-coupled receptors (GPCRs) involved in host 
defense against pathogens in the innate immune system. FPRs function is best 
known in phagocytic leukocytes (e.g.neutrophils and monocytes) that, in response 
to microbial chemoattractants, migrate and accumulate at sites of infection, where 
they release ROS and other factors to combat invading microorganisms (18).  
FPR1, namely the high affinity receptor, is activated by nanomolar concentrations 
of fMLF. FPR2 is a promiscuous receptor activated in response to high 
concentration of fMLF, viral peptides (gp41 envelope protein of the HIV-1 virus), 
bacterial peptides (Hp2-20, a non-formyl peptide derived from Helicobacter pylori), 
endogenous peptides [Amyloid beta (1–42) fragment, prion protein fragment 
PrP(106–126), cleaved soluble fragments of Urokinase-type plasminogen 
activator receptor (uPAR)], and synthetic peptides. Hp2-20 (20), and F2L (21) are 
natural ligands for FPR3. The synthetic peptide WKYMVm is mainly a FPR2 and 
FPR3 agonist (20) (Fig. 3). 
Although FPRs expression has been initially described in immune cells, it is 
becoming increasingly clear that FPRs are also expressed in other cell types and 
tissues (22). 
 
2.5 FPRs signal transduction pathways  
FPRs are G protein-coupled receptors (GPCRs) that can be inhibited by pertussis 
toxin indicating that the G proteins associated with these receptors belong to the 
Gi family (18).  
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It has been well established that GPCRs are subjected to desensitization. 
‘Homologous desensitization’ is rapidly induced by binding of cognate agonists in 
association with receptor phosphorylation and internalization (19). These 
receptors may also be ‘heterologously’ desensitized by agonists that activate other 
unrelated receptors; receptor desensitization relies mainly on G protein-coupled 
receptor kinases (GRKs) family-mediated receptor phosphorylation (18).  
However, receptor phosphorylation alone is not enough to prevent G protein 
binding and activation. For homologous desensitization, the binding of arrestins 
with phosphorylated receptor prevents G protein binding, leading to receptor 
inactivation (23).  
FPRs activate distinct patterns of intracellular signaling indicating that selective 
activation of intracellular signaling cascades may underlie different functional 
responses (24). After binding of its agonists, FPRs activate the heterotrimeric G 
protein, which dissociates into α and βγ subunits, activating the phospholipase C 
(PLC) and the phosphatidylinositol 3-kinase (PI3K) (25). Hydrolysis of 
phosphatidylinositol 4, 5-biphosphate (PIP2) by PLC generates IP3, which 
releases calcium from endoplasmic reticulum stores. The release of calcium is a 
necessary condition for the chemotaxis of neutrophils (26). Hydrolysis of 
phosphatidylinositol 4, 5-biphosphate (PIP2) by PLC also generates 
diacylglycerol (DAG), which activates various isoforms of protein kinase C 
(PKC). 
The phosphatidylinositol 3-kinase (PI3K) - Akt / PKB pathway is also activated, 
in particular the PI3Kγ, which is the isoform more associated with 
chemoattractant receptors. Other intracellular events include: the activation of 
CD38, a surface glycoprotein which, acting on NAD
+
, activates a cascade of 
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events that lead to increased concentrations of cyclic AMP (cAMP) and the 
release of Ca
2+ 
at the extracellular level, phospholipase A2 and D, RAS-dependent 
activation of the mitogen-activated protein kinases (MAPK) ERK1/ERK2, JNK 
and p38MAPK cascade and also some other protein tyrosine kinases. In 
particular, the MAPK cascade is involved in several physiological processes 
including growth, differentiation and cell migration, apoptosis and immune 
responses (27). 
One of the most important biochemical responses triggered by FPRs stimulation is 
the activation of the multimeric complex of the NADPH oxidase. ERKs are 
involved in the phosphorylation of p47
phox
 and represent one target of PKC in the 
signal transduction pathway activated by FPRs. p47
phox
 cytosolic subunit can be 
considered a regulatory subunit of the enzyme complex, because its 
phosphorylation allows the translocation of cytosolic components of the NADPH 
oxidase complex (28).  
An additional control of NADPH oxidase activation is determined by the GTPase 
Rac1/2, which, directly interacts with the N-terminal tetratricopeptide repeat 
(TPR) domain of p67
phox
 (29, 30) and serves as an “adaptor” by providing a stable 
platform for the interaction with the catalytic component gp91
phox
. 
 
2.6 FPRs role in human diseases 
Accumulating evidences show that FPRs possess important regulatory effects in 
multiple diseases including inflammation, amyloidosis, Alzheimer’s disease, prion 
disease, acquired immunodeficiency syndrome, obesity, diabetes and cancer (27). 
FPRs are expressed in abundance on cells of the host defence system; however, 
they may have distinctly different functions beyond simple pathogen recognition.  
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The ability of FPRs to recognize endogenous ligands appears to be essential for 
the regulation of non-infectious inflammation, wound healing and tissue 
regeneration. Recently, FPRs involvement was described in the repair of 
intestinal, gastric and nasal epithelial cells after inflammatory processes (27). 
FPRs seem to exert homeostatic functions in epithelia. Alterations in the colonic 
film mucin layer, increased epithelial permeability and defective mucosal wound 
healing have been observed in FPR1−/− mice during chronic dextran sodium 
sulphate (DSS)-induced colitis. Furthermore, knockout of FPR2 in mouse colon 
epithelial cells impaired mucosal recovery after damage (27). 
Moreover, FPRs activation promotes angiogenesis in various inflammatory 
settings in response to both exogenous and endogenous ligands. FPRs also exert a 
complex role in cancer. They inhibit tumor growth and/or the angiogenic response 
in both the stomach and colon; by contrast, in glioblastoma models, FPR1 is 
needed to stimulate angiogenesis and tumor growth (31). 
Both in inflammatory and epithelial cells, FPRs exert their action through a 
structural and functional interaction with the urokinase-type plasminogen 
activator (uPA) receptor (uPAR). How these receptors interact to recognize their 
ligands, transduce their signals and contribute to disease pathogenesis are basic 
questions currently under investigation that would open up new avenues for the 
future management of inflammation-related diseases. 
 
2.7 The urokinase receptor: a versatile signaling orchestrator  
The urokinase-type plasminogen activator receptor (uPAR) is a glycosyl-
phosphatidyl-inositol (GPI)-anchored cell-surface receptor involved in many 
physiological and pathological events which require remodeling of the 
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extracellular matrix, such as embryogenesis, inflammation, tumor invasion and 
metastasis (32). uPAR traditional role was considered the focusing of the 
urokinase (uPA) proteolytic activity on the cell surface; however, different uPAR 
activities have been demonstrated in the last years. Indeed, despite the lack of a 
transmembrane domain, uPAR can activate intracellular signaling through lateral 
interactions with other cell surface receptors, such as integrins, receptor tyrosine 
kinases, and G-protein–coupled chemotaxis receptors (33). 
uPAR itself is an adhesion receptor; it binds directly vitronectin (VN), a protein of 
the provisional ECM (34). 
 
2.8 uPAR functions 
uPAR is a single chain glycoprotein which binds uPA with high affinity (Kd = 10
-
10
M) and concentrates the activity of the enzyme to the cell surface. The receptor 
also binds, with the same affinity, the inactive form of urokinase (pro-uPA), 
facilitating its activation (35). 
uPAR is synthesized as a single polypeptide chain of 313 amino acids and 
undergoes a post-translational maturation process during which, at the C-terminal, 
a peptide of 30 amino acids is removed and a GPI tail is added. This tail is 
essential for anchoring of receptor to the plasma membrane and allows uPAR 
association with the plasma membrane rich in cholesterol microdomains, also 
called "lipid rafts", involved in signal transduction. 
uPAR molecular weight is between 50 and 60 kDa; the heterogeneity depends on 
the presence of 5 potential sites of N-glycosylation that modulate the affinity of 
the receptor for their ligands (35). 
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The mature receptor is formed by three homologous domains (DI, DII, and DIII, 
numbered from the N-terminus). DIII domain anchors the receptor to the 
membrane through the GPI tail, DII domain connects DIII to the N-terminal DI, 
which interacts with the amino-terminal fragment (ATF) of uPA.  
uPA is a serine protease which cleaves plasminogen, generating the active 
protease plasmin. Plasmin cleaves and activates matrix metalloproteases (MMPs). 
Both plasmin and MMPs degrade many ECM components and activate growth 
factors or liberate them from ECM sequestration. 
uPA can also induce a cascade of intracellular signaling independent of its 
catalytic activity. These effects are mediated by uPA binding, in active or inactive 
form (pro-uPA), to uPAR, through which, uPA can stimulate cell growth, 
motility, adhesion, and transcription of specific genes (35). 
uPAR also binds the somatomedin B domain of VN through a specific binding 
domain exposed on the DI/DII interface of the receptor (34). uPAR promotes 
metastasis of human malignancies by engaging VN through the activation of a cell 
signaling to Rac-1 and induces phenotypic changes consistent with hypoxia-
induced EMT (34, 36) (Fig. 4A).  
 
2.9 uPAR forms 
uPAR can be cleaved between domains DI and DII, thus generating a soluble DI 
fragment and  membrane anchored DIIDIII-uPAR forms.  
The release of domain DI occurs following a proteolytic cleavage by several 
proteases including trypsin, chymotrypsin, elastase, cathepsin G, plasmin and uPA 
itself. uPA can cut uPAR in two sites: Arg
83
- Ala
84
 and Arg
89
- Ser
90
. A cut in the 
Arg
83
-Ala
84
 site leads to the N-terminal exposure of an epitope corresponding to 
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amino acids 88-92 (SRSRY), thus generating the DIIDIII-uPAR88-92, able to 
interact with FPRs and involved in cell migration (Fig. 4A). A cut in the second 
site destroys the SRSRY region and generates DIIDIII-uPAR, unable to interact 
with FPRs. 
In addition to the membrane-anchored uPAR, soluble receptor forms (suPAR, 
DIIDIII-suPAR88-92, DIIDIII-suPAR) are released after cleavage of the GPI 
anchor by phospholipase C or D (37) (Fig. 4B).  
 
2.10 uPAR molecular interactions and signaling 
The identification of transmembrane receptors that cooperate with uPAR has 
contributed to elucidate the uPAR-dependent cell signaling mechanisms. In fact, 
the stimulation of uPAR regulates adhesion, migration and cell proliferation, 
protects against apoptosis and anoikys, and induces EMT, independently from 
uPA enzymatic activity (38). 
uPAR can activate intracellular signaling through lateral interactions with other 
cell surface receptors, such as integrins, receptor tyrosine kinases, and FPRs. 
uPAR ability to regulate integrin activity plays a key role in cell adhesion, 
migration, proliferation, and survival. Integrin-binding sites have been identified 
in uPAR domain DII (peptide D2A, residues 130–142) and in uPAR domain DIII 
(residues 240–248). Soluble D2A abolishes uPAR-alphavbeta3 and uPAR-
alpha5beta1 co-immunoprecipitation, indicating that it can bind both of these 
integrins; in addition, D2A has chemotactic activity that requires alphavbeta3 and 
activates alphavbeta3 signaling pathways (39). The specific sequence identified in 
the uPAR domain DIII binds the alpha5beta1 integrin; substituting a single amino 
acid in that region (S245A) impairs uPAR binding to the purified integrin (40). 
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As for VN and uPA binding, the uPAR/integrin association requires the intact 3-
domain structure of uPAR (41). 
uPAR-integrin interactions activates the MAPK cascade, in particular ERK 1/2, 
with the involvement of non-receptor tyrosine kinase src, tyrosine-kinase family 
src (Hck, Fgr, Fyn) and focal adhesion-associated protein kinase (FAK). 
Activation of these intracellular mediators then lead to different results depending 
on the cell type (38).  
uPAR interaction with FPRs occurs at the cell surface and is required for both 
uPA- and fMLF-dependent cell migration. Cross-talk between uPAR and FPRs 
occurs through a chemotactic domain located in the DI–DII linker region of 
uPAR, the SRSRY sequence (amino acids 88–92) exposed upon proteolytic 
cleavage of the receptor (42).  
It has been proposed that the SRSRY sequence is masked in cell-surface uPAR 
and that uPA binding to uPAR determines a conformational modification of the 
receptor with the exposure of the chemotactic SRSRY domain that, in turn, binds 
and activates FPRs, thus inducing chemotaxis (43).  
A soluble cleaved form of uPAR, lacking the DI domain and exposing at the N-
terminus the SRSRY sequence, was also identified as a ligand for FPRs in human 
plasma and urine (44).  
uPAR interacts with several other molecules such as growth-factor receptors as 
the receptors for the epidermal growth factor (EGFR) and for the PDGFR-beta, 
which appear to mediate uPAR-associated proliferative signal (38). 
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2.11 Aim of study 
SSc is characterized by severe and often progressive fibrosis of the skin and 
multiple internal organs. The mechanisms responsible for these alterations remain 
obscure, although excessive ROS-mediated oxidative stress has been implicated. 
This research project, starting from recent experimental evidences demonstrating 
the involvement of the innate immunity receptors in the pathogenesis of chronic 
inflammatory diseases, has the aim to clarify a possible role of FPRs and their 
cross-talk with uPAR in ROS production in normal and SSc skin fibroblasts. 
Furthermore, this study was also undertaken to elucidate the intracellular 
signaling pathways involved in ROS generation and to analyze the effects of the 
cross-talk between FPRs/uPAR/1integrin on FPRs-mediated ROS production in 
fibroblast cells. 
The identification of specific factors or pathways involved in the deregulation of 
the fibrotic process offers the potential for the development of therapeutic 
strategies for fibrotic diseases, which are still characterized by high morbidity and 
mortality. 
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3 MATERIALS AND METHODS 
3.1 Peptides and chemicals 
The hexapeptide Trp-Lys-Tyr-Met-Val-D-Met-NH2 (WKYMVm) was synthesized and 
HPLC puriﬁed (95%) by Innovagen (Lund, Sweden), the peptide uPAR84–95 was 
synthesized by PRIMM (Milan, Italy), uPA N-terminal fragment (ATF-uPA) was from 
American Diagnostica (Greenwich, CT) and N-Formyl-L-methionyl-L-leucyl-L-
phenylalanine (fMLF) was from Calbiochem (La Jolla, CA). TRIzol solution was from 
Invitrogen FischerScientiﬁc (Illkirch, France), and DNA ladder and Moloney leukemia 
virus reverse transcriptase were from Promega (Madison, WI). Protein concentration 
was estimated with a modiﬁed Bradford assay (Bio-Rad Laboratories). ECL Plus was 
from GE Healthcare (Buckinghamshire, UK), and 29,79-dichlorodihydroﬂuorescein 
diacetate (DCHF-DA) was from Molecular Probes (Invitrogen, Paisley, UK). The 
mixture of protease and phosphatase inhibitors was from Calbiochem. Mouse anti-
FPR1, rabbit anti-FPR2, mouse anti-FPR3, mouse anti-gp91
phox
, rabbit anti-p67
phox
, 
mouse anti phospho-ERK and rabbit anti ERK 2 were from Santa Cruz Biotechnology 
(Santa Cruz, CA); mouse anti-tubulin and rabbit anti-actin were from Sigma-Aldrich 
(St. Louis, MO); rabbit anti-uPAR84–95 (also called IB in the text) was from PRIMM; 
mouse anti-Rac1 was from Upstate Biotechnology (Lake Placid, NY); mouse 
monoclonal anti-uPAR ADG3937 was from American Diagnostica; mouse monoclonal 
R3 and mouse monoclonal R4 were kindly provided by Gunilla Høyer-Hansen (Finsen 
Laboratory, Copenaghen, Denmark). Secondary anti-mouse and anti-rabbit Abs coupled 
to HRP were from Bio-Rad (Munchen, Germany). PD98059 and NSC23766 were from 
Calbiochem, P25 from PRIMM, Selumetinib (AZD6244) from AstraZeneca and C37 
from the NCI/DTP Open Chemical Repository (Available from: http://dtp.cancer.gov); 
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they were dissolved in dimethyl sulfoxide (DMSO), stored at −20°C, and added to the 
culture at final concentrations indicated in the text. 
 
3.2 Tissues and patients samples 
Eight females and two males affected by SSc, observed from January 2011 to December 
2013 in the Day Hospital of the Department of Translational Medical Sciences of the 
University of Naples Federico II, were classiﬁed according to the American College of 
Rheumatology criteria (45) as having limited cutaneous SSc (lcSSc; n = 6) or diffuse 
cutaneous (dcSSc; n = 4) (3) and included in the study. All patients signed a written 
informed consent according to the guidelines of the institutional review board for the 
use of humans in research. The mean age of patients was 54 y (range, 31–70 y). Disease 
duration was calculated from the time of onset of the ﬁrst clinical event (other than 
Raynaud’s phenomenon) that was a clear manifestation of SSc. Patients were classiﬁed 
as having an early-stage (n = 4) or late stage (n = 6) SSc, according to disease duration 
(˂5 y for early-stage limited cutaneous SSc and ˂3 y for early-stage diffuse cutaneous 
SSc) and skin histopathology (46). We considered clinically involved skin for values of 
skin thickness ≥ 2, according to the modiﬁed Rodnan skin thickness score. All patients 
with the diffuse form had involvement of dorsal arm and/or thorax. To reduce 
variability among the patients, we admitted for study only SSc patients positive for 
antinuclear Abs, showing a speckled pattern as evaluated by indirect 
immunoﬂuorescence and ELISA. Because antinuclear Ab positivity may be considered 
not sufﬁcient for subtype characterization, other clinical measures were investigated; in 
particular, all patients with diffuse cutaneous SSc presented anti–SCL-70 topoisomerase 
I positivity, and patients with limited cutaneous SSc showed serum anticentromere 
(CENP-B) positivity. All patients were washed out from steroid treatment 30 d before 
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the biopsy was taken. Other treatments were allowed (proton pump inhibitors, 
vasodilators, and so on). Patients who could not undergo washout because of the severe 
organ complications were not evaluated. Patients with symptoms overlapping with those 
of other autoimmune, rheumatic, and/or connective tissue diseases were excluded from 
the study. Control donors were matched with each scleroderma patient for age, sex, and 
biopsy site, and control samples were processed in parallel control (eight females and 
two males; mean ± SD age, 43 ± 15 y). 
 
3.3 Cell cultures 
Surgical fragments were mechanically dissociated under a light microscope and 
subjected to trypsinization for 30 min at 37˚C, as described previously (47). After two 
PBS washings, cells were plated and cultured in monolayer in DMEM (Life 
Technologies Carlsbad, CA) supplemented with 10% heat inactivated FBS (Life 
Technologies), 100 U/ml penicillin G sodium, and 100 mg/ml streptomycin sulfate, at 
37˚C, in a humidiﬁed atmosphere of 5% CO2. Fibroblasts from normal subjects and 
from patients with SSc were used between the 3rd and 10th passage in culture.  
The BJ (human foreskin ﬁbroblasts), the HGF-1 (human gingival fibroblasts) and the 
MRC-5 (human lung fibroblasts) were from ATCC (LGC Standards, Milan, Italy) and 
were grown in DMEM (Life Technologies) supplemented with 10% FBS. 
BJ cells, on which we have focused our studies, were obtained from ATCC at the 6
th
 
passage, subcultured and frozen in stock vials; they were used between the 1
st
 and 10
th
 
passage in culture.  
The H460 (cell lung cancer) were obtained from ATCC and grown in RPMI 1640 
medium (Life Technologies) supplemented with 10% FBS. 
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3.4 RNA puriﬁcation and analysis 
Total cellular RNA was isolated by lysing cells in TRIzol solution, according to the 
supplier’s protocol (43). RNA was precipitated and quantitated by spectroscopy. Five 
micrograms of total RNA was reversely transcribed with random hexamer primers and 
200 U murine Moloney leukemia virus reverse transcriptase. One microliter of reverse-
transcribed DNA was then ampliﬁed for FPR1, FPR2, FPR3, and GAPDH using 
speciﬁc primers. The primers for FPR1 were 5’-ATGGAGACAAATTCCTCTCTC 
(sense) and 3’-CACCTCTGCAGAAGGTAAAGT (antisense); for FPR2 were 5’-
CTTGTGATCTGGGTGGCTGGA (sense) and 3’-CATTGCCTGTAACTCAGTCTC 
(antisense) (43); and for FPR3 were 5’-AGTTGCTCCACAGGAATCCA (sense) and 
3’-GCCAATATTGAAGTGGAGGATCAGA (antisense) (48). The primers for 
GAPDH were 5’-GCCAAAGGGTCATCATCTC (sense) and 3’-
GTAGAGGCAGGGATGATGTTC (antisense). PCR products, together with a DNA 
ladder as a size standard, were separated on a 1% agarose gel, stained with ethidium 
bromide, and quantiﬁed with the image analysis system ChemiDoc XRSn (Bio-Rad 
Laboratories). 
 
3.5 Western blot analysis 
Immunoblotting experiments were performed according to standard procedures (43). 
Brieﬂy, cells were harvested in lysis buffer (50 mM HEPES, 150 mM NaCl, 10% 
glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl2, 10 mM NaF, 10 mM sodium 
pyrophosphate, and 1 mM Na3VO4) supplemented with a mixture of proteases and 
phosphatases inhibitors. Fifty micrograms of protein was electrophoresed on a 10% 
SDS-PAGE and transferred onto a polyvinylidene ﬂuoride membrane. The membrane 
was blocked with 5% nonfat dry milk and probed with speciﬁc Abs: mouse anti-FPR1 
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(1 g/ml), rabbit anti-FPR2 (1 g/ml), mouse anti-FPR3 (1 g/ml), mouse anti-uPAR 
R4 (1 g/ml), mouse anti-uPAR84–95 (1 g/ml), mouse anti-Rac1 (1 g/ml), mouse anti 
phospho-ERK (5 g/ml), rabbit anti-ERK 2 (1 g/ml), mouse anti-gp91phox (1 g/ml), 
rabbit anti-p67
phox
 (1 g/ml), mouse anti-tubulin (0.5 g/ml), and rabbit anti-actin (0.5 
g/ml). Finally, washed ﬁlters were incubated with HRP-conjugated anti-rabbit or 
antimouse Abs. The immunoreactive bands were detected by a chemiluminescence kit 
and quantiﬁed by densitometry (ChemiDoc XRS, BioRad). 
 
3.6 Co-immunoprecipitation  
BJ ﬁbroblasts (5 x 106 cells/sample) were plated in 100-mm dishes for 24 h. Cells were 
lysed in radioimmunoprecipitation assay buffer supplemented with a mixture of 
proteases and phosphatases inhibitors and incubated with mouse nonimmune serum 
(Jackson ImmunoResearch Laboratories, Suffolk, UK) and 10% protein A-conjugated 
Sepharose (GE Healthcare, Milan, Italy) for 2 h at 4˚C. After centrifugation, the 
supernatants were incubated with 2 µg/ml of the R4 monoclonal anti-uPAR Ab or with 
nonimmune mouse Igs for 2 h at 4˚C and then with 10% protein A–Sepharose for 30 
min at room temperature. The immunoprecipitates were washed in 
radioimmunoprecipitation assay buffer, subjected to 10% SDS-PAGE, and analyzed by 
Western blot analysis using a polyclonal Ab directed against FPR1. 
 
3.7 Determination of ROS 
The BJ cells were plated overnight at 2 x 10
4 
cells/well in 96-well plates using DMEM 
containing 10% FBS. Cells were incubated with DCHF-DA (5 μM) for 30 min in the 
dark at 37˚C; after incubation, cells were washed twice and treated with medium alone, 
fMLF (10
-4
 M; 10
-8
 M), uPAR84–95 (10
-8
 M), WKYMVm peptide (10
-8
 M), H2O2 (1 
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mM), as a positive control, in the presence or in the absence of P25 (50µM), anti-
uPAR84–95 (5 µg/ml), PD98059 (50 µM), NSC23766 (25 µM), C37 (10 µM) and 
Selumetinib (2,5 µM) for 5, 15, 30 and 60 minutes at 37˚C in a humidiﬁed 5% CO2 
incubator. The esteriﬁed form of DCHF-DA permeate cell membranes before being 
deacetylated by intracellular esterases. The resulting compound, 
dichlorodihydroﬂuorescein, reacts with ROS, producing an oxidized ﬂuorescent 
compound, dichloroﬂuorescein (DCHF), which we detected at a wavelength of 535 nm 
by a microplate reader (Tecan Trading AG, Switzerland).  
Intracellular ROS generation by primary normal and SSc fibroblasts in a 6-well plate, 
after loading cells with DCHF-DA, was measured by ﬂow cytometry (FACSCalibur). 
Cell monolayers were treated with medium alone, ATF-uPA (10
-8
 M), uPAR84–95 (10
-9
 
M), WKYMVm peptide (10
-9
 M), or H2O2 (1 mM), as a positive control, for 30 min at 
37˚C in a humidiﬁed 5% CO2 incubator. Cells were then washed twice, and 5 µM 
DCHF-DA was added for 30 min in the dark at 37˚C. After incubation, cells were 
washed, trypsinized for immediate analysis, and resuspended in PBS. A total of 10
4
 
events were acquired for each sample in all cytoﬂuorimetric analysis, and intracellular 
ROS formation was detected as a result of the oxidation of DCHF which can be detected 
by ﬂow cytometry at a wavelength of 520 nm (FL1). Results are expressed as 
percentage of increase of mean ﬂuorescence intensity in respect to untreated cells. 
 
3.8 Flow cytometric analysis of surface molecules 
Flow cytometric analysis of cell surface molecules was performed as previously 
described (43). Briefly, after saturation of non specific binding sites with total rabbit 
IgG, cells were incubated for 20 min at +4°C with specific or isotype control antibodies. 
For indirect staining this step was followed by a second incubation for 20 min at +4°C 
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with an appropriate anti-isotype-conjugated antibody. Finally, cells were washed and 
analyzed with a FACSCalibur Cytofluorometer using Cell Quest software (Becton & 
Dickinson, San Fernando, CA). A total of 10
4
 events for each sample were acquired in 
all cytofluorimetric analyses. 
 
3.9 Determination of Rac1 activity and association with p67
phox
 
The BJ cell line was incubated at 37˚C with or without speciﬁc agonists for the 
indicated times, washed with phosphate-buffered saline, and then lysed in MLB buffer 
(10µg/mL aprotinin and 10 µg/mL leupeptin) in the presence of protease and 
phosphatase inhibitors. After being centrifuged at 12,000 × g for 5 min at 4°C, the same 
amount of total protein from clarified lysate was incubated with GST-PBD (p21-binding 
domain of human PAK-1) to precipitate GTP-bound Rac1 at 4°C on a rotator for 1 h 
and then the beads were pelleted through centrifugation at 14,000 × g for 10 seconds at 
4°C. The resulting pellet was resuspended in Laemmli buffer, boiled for 5 min and 
subjected to Western blot analysis with anti-Rac1 Ab or with anti p67
phox
 Ab. Total 
Rac1 and p67
phox 
in each sample was also determined, as a loading control. 
 
3.10 Histology and immunohistochemistry 
After clinical evaluation, a 3-mm skin punch was taken from the most representative 
area of each patient affected by SSc and from 10 normal subjects as a control. Each 
specimen was ﬁxed in 10% buffered formalin, embedded in parafﬁn, and serial 
sectioned (4-mm-thick sections). One section for each case was stained with H&E and 
the others stained by immunohistochemistry (labeled streptavidin biotin standard 
technique) with specific antibodies. Cells showing a deﬁnite black staining conﬁned to 
the nucleus or cytoplasm were judged positive. All slides were examined in a double-
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blinded fashion by two investigators, and the ﬁnal staining for each case was expressed 
as the percentage of positive cells among the total number of counted cells (at least ﬁve 
high-power representative ﬁelds).   
 
3.11 Statistical analysis 
All the experiments were performed at least in triplicate. The results are expressed as 
mean ± SEM. Values from groups were compared using a paired Student t test (49). 
Differences were considered signiﬁcant when p ˂ 0.05. 
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4. RESULTS 
4.1 In vivo expression of FPR1, FPR2, and FPR3 in human normal and SSc skin 
ﬁbroblasts 
N-formyl peptide receptors (FPRs), a family of pattern recognition receptors, possess 
important regulatory effects in multiple pathological conditions, including inflammation 
and cancer. 
To test the possibility that FPRs are involved in the pathogenesis of SSc, we 
investigated whether they were expressed on fibroblasts from skin punch biopsies of 10 
patients affected by SSc and of 10 normal subjects, as a control. At histological 
analysis, (H&E staining, in Fig. 5A a representative case), all enrolled SSc cases (six 
limited cutaneous and four diffuse cutaneous) showed dermal ﬁbrosis that 
characteristically involved the subcutis, associated with chronic inﬂammatory inﬁltrate, 
mainly localized at the interface between the deep dermis and subcutis and around 
vessels (a–c), as compared with normal skin (d). All the evaluated cases showed an 
increased positivity for FPR1 (e–g), FPR2 (i–k), and FPR3 (m–o), compared with that 
observed in normal skin (h, l, p), used as a control.  
FPR1 was found diffusely positive in ﬁbroblasts, endothelial cells, and lymphocytes. 
FPR2 was expressed in several but not all ﬁbroblasts, whereas FPR3 was seen 
extensively expressed only in ﬁbroblasts.  
 
4.2 In vitro expression of FPR1, FPR2, and FPR3 in human normal and SSc skin 
ﬁbroblasts 
We also examined FPRs expression in primary cultures of skin ﬁbroblasts from 10 
normal subjects and 10 SSc patients. The analysis of total RNA by RT-PCR showed 
expression of all three FPRs (Fig. 5B), that resulted upregulated in SSc ﬁbroblasts as 
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compared with normal ﬁbroblasts, with a signiﬁcant increase for FPR2 and FPR3 (fold 
increase SSc versus normal ﬁbroblasts: FPR1 2.6; FPR2 5.17; and FPR3 6.08) (Fig. 
5B).  
We then investigated FPRs expression in normal and SSc ﬁbroblasts at a protein level. 
Western blot analysis with speciﬁc antibodies demonstrated that ﬁbroblasts synthesize 
all the three FPRs (Fig. 5C). Unexpectedly, we observed a different pattern of increase 
of FPR protein expression as compared with mRNA levels. Indeed, FPR1 and FPR3 
expression increased in SSc ﬁbroblasts as compared with normal ﬁbroblasts (fold 
increase SSc versus normal ﬁbroblasts: FPR1 4.07; FPR3 1.3; p ˂ 0.05), whereas FPR2 
was not signiﬁcantly upregulated (fold increase SSc versus normal ﬁbroblasts 1.02) 
(Fig. 5C).  
These experiments demonstrate that both normal and SSc ﬁbroblasts express FPRs; 
moreover, SSc ﬁbroblasts show an overexpression as compared with normal cells. It is 
conceivable that posttranscriptional mechanisms may regulate the expression of these 
receptors in normal and SSc ﬁbroblasts, causing a different expression pattern at mRNA 
and protein level. The histology data are in agreement with the in vitro observations, 
showing a lower expression of FPR2, at a protein level, in SSc ﬁbroblasts, compared 
with FPR1 and FPR3. 
 
4.3 In vivo and in vitro expression of uPAR forms in human foreskin fibroblasts  
Several functions of FPRs occur through the interaction with the urokinase-type 
plasminogen activator (uPA) receptor (uPAR) (41).  
uPAR cleavage contributes to the impaired angiogenesis observed in SSc patients (50). 
Inactivation of uPAR gene induces dermal and pulmonary fibrosis and peripheral 
microvasculopathy in mice. Moreover, native full-length uPAR expression is 
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significantly decreased in the skin of SSc patients, as assessed by a monoclonal anti-
uPAR/domain DI antibody (51).  
Thus, although full-length uPAR expression is significantly downregulated in SSc 
dermis, we hypothesized that the DII-DIII-uPAR88-92 form, able to interact with FPRs, 
could instead be increased. To confirm our hypothesis, we investigated the expression 
of the different uPAR forms in SSc skin biopsies, by immunohistochemistry with 
specific antibodies. In particular, we used the R3 monoclonal antibody, which 
recognizes domain DI (52), the IB polyclonal antibody, speciﬁcally directed against the 
88
Ser-Arg-Ser-Arg-Tyr
92
 sequence of uPAR (53), and the ADG3937 monoclonal 
antibody, recognizing an epitope located in the domains DII+DIII.  
SSc skin biopsies revealed dermal fibrosis showing prominent involvement of the deep 
dermis and the subcutaneous fat, admixed with chronic inflammatory infiltrate, mostly 
confined deeply around vessels of the subcutis. As expected, all biopsies showed an 
absent/low staining for R3, in fibroblasts, endothelial cells and lymphocytes. 
Conversely, IB was found positive in fibroblasts, endothelial cells and lymphocytes of 
all specimens; finally, ADG3937 was expressed only in 4 out 14 selected cases (Fig. 
6A).  
In Figure 6B is reported a staining for IB on a skin biopsy of localized scleroderma 
previously evaluated for FPR1, FPR2 and FPR3 expression: fibroblasts, lymphocytes 
and endothelial cells were strongly positive for IB, as reported for FPRs antibodies (see 
Fig. 5A). 
We also investigated DII-DIII-uPAR88–92 expression in primary cultures of normal and 
SSc ﬁbroblasts by Western blot analysis, using the polyclonal IB antibody. Figure 6C 
shows that SSc ﬁbroblasts markedly overexpressed DII-DIII-uPAR88–92 (fold increase 
SSc ﬁbroblasts versus normal cells: 4.7; p ˂ 0.05).  
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Thus, in SSc fibroblasts, full length uPAR down-regulation, most probably due to the 
induction of the uPA pathway (47), is accompanied by increased membrane expression 
of DII-DIII-uPAR88-92, containing the chemotactic sequence able to interact with 
overexpressed FPRs. 
 
4.4 Expression of FPRs in human normal ﬁbroblasts; uPAR expression and direct 
interaction with FPR1 in human normal foreskin fibroblasts 
In order to further study FPRs functions and their possible cross-talk with uPAR in 
fibroblast cells, we sought a fibroblast cell line to be used as a model.  
We first investigated, by cytofluorimetric analysis, FPRs expression in three human 
fibroblast cell lines from different sources: normal foreskin fibroblasts (BJ cells), 
normal gingival fibroblasts (HGF-1 cells), and normal lung fibroblasts (MRC5 cells). 
Normal ﬁbroblasts from the three cell lines, even with a different pattern of expression, 
synthesized all the three members of the FPRs family (Fig. 7A).  
Thus, for subsequent studies on FPRs functions, we focused on the BJ fibroblast cell 
line. BJ fibroblast cells were established from normal human foreskin and have the 
ability to proliferate to a maximum of 72 population doublings before the onset of 
senescence (54). 
BJ fibroblasts, tested at different times of culture, expressed both forms of uPAR, but 
mostly the native intact form, thus confirming in vivo observations (51) (Fig. 7B). 
Since both intact and cleaved DII-DIII-uPAR88–92(55), either on the cell membrane (56) 
or in a soluble form (44) can interact with FPRs, in many cell types (33), to investigate 
whether such interaction could also occur in normal fibroblast cells, a pull-down 
experiment was carried out in human skin fibroblasts from the BJ cell line.  
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In BJ cells, immunoprecipitation with a monoclonal anti-uPAR antibody and Western 
blot analysis of the immunoprecipitate with polyclonal anti-FPR1 antibodies revealed a 
band corresponding to FPR1 that was absent in the same lysate immunoprecipitated 
with nonimmune Igs. As a control, a corresponding band was evidenced in BJ total cell 
lysates subjected to Western blot analysis with anti-FPR1 antibodies (Fig. 7C).  
Therefore, a structural interaction between uPAR and FPR1 can occur in normal 
fibroblast cells and exert functional effects. 
 
4.5 Effects of fMLF, WKYMVm peptide, and uPAR84–95 on ROS production in human 
normal foreskin fibroblasts 
We have already demonstrated that FPRs stimulation promotes α-smooth muscle actin 
expression in primary cultures of normal dermal fibroblasts as well as motility, matrix 
deposition, and αvβ5 integrin expression, thus playing a role in fibrosis and in the 
fibroblast-to-myofibroblast transition (57).  
In this thesis, we sought to investigate whether FPRs stimulation and their cross-talk 
with uPAR could induce radical oxygen species (ROS) generation in fibroblast cells, 
thus playing a role in some processes involved in SSc, such as tissue remodeling and 
fibrosis.  
It is well established that low/moderate concentrations of ROS are involved in the 
redox-dependent regulation of multiple signal transduction pathways and in essential 
biological processes, including cell adhesion, migration, proliferation, differentiation, 
and survival (58, 59). However, at high levels, ROS are known to exert very damaging 
effects through oxidative stress. This is caused by an imbalance between the ROS 
production and the ability of cellular antioxidant mechanisms to detoxify the reactive 
intermediates, thus amplifying the risk of cellular dysfunction and oxidative injury (58). 
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There are accumulating evidences suggesting a role of the oxidative stress in the 
pathogenesis of SSc (1); indeed, it has been shown that ROS contribute to the persistent 
ﬁbrotic phenotype of SSc ﬁbroblasts (10) and that antioxidants, such as 
epigallocatechin-3gallate, can reduce ECM production, function, and activity of dermal 
ﬁbroblasts from SSc patients (11).  
Several studies have described, among the various properties of FPRs, the capability to 
induce ROS generation upon binding to their speciﬁc ligands (60). Interestingly, SSc 
neutrophils may induce local production of ROS upon fMLF stimulation in endothelium 
(60).  
On these basis, we investigated the effects of FPRs activation and cross-talk with uPAR 
on ROS release from normal fibroblasts, using the BJ cell line as a model.  
To this aim, we evaluated ROS levels after stimulation with speciﬁc FPRs agonists, 
such as fMLF, the synthetic peptide WKYMVm, and the soluble uPAR84-95 peptide, 
containing the uPAR-derived 
88
SRSRY
92
 sequence, able to bind and activate FPRs. The 
intracellular ROS levels were determined after 5, 15, 30, and 60 minutes of stimulation 
with fMLF, WKYMVm peptide, and uPAR84–95, and compared with unstimulated cells.  
As shown in Figure 8, dermal fibroblasts from the BJ cell line responded in a signiﬁcant 
manner to all the three stimuli (p ˂ 0.05), thus suggesting that FPRs stimulation could 
be involved in ROS production in normal fibroblast cells as well as their cross-talk with 
uPAR, through the 
88
SRSRY
92
 sequence. 
 
4.6 FPRs-uPAR-Integrin crosstalk as a potential player in ROS generation by human 
normal foreskin fibroblasts 
uPAR is an important signaling partner of FPRs at the cell-surface. Moreover, a large 
body of evidence shows that uPAR also requires integrins as co-receptors. In tumor 
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cells, uPAR overexpression controls the mechanisms of cell migration and invasion by 
recruiting integrins and FPR1 at the cell surface and regulating their signaling pathways 
(55). Thus, we hypothesized that FPRs could regulate ROS production in fibroblast 
cells through the same mechanism. 
To test our hypothesis, ROS production assay was performed in the presence of IB, a 
polyclonal antibody directed against the uPAR88–92 region involved in uPAR interaction 
with FPRs (44) and in the presence of the P25 peptide, which has been shown to disrupt 
uPAR interactions with β1 or β2 integrins (61). 
Figure 9 shows that treatment of BJ cells with the IB antibody and the P25 peptide 
totally inhibited FPRs-mediated ROS production, in response to their specific agonists, 
fMLF and the WKYWM peptide. Non immune antibodies and a scrambled peptide, 
used as controls, did not exert any effect. 
These results suggest that FPRs could control ROS production by interacting with 
uPAR and forming a complex with integrins, as already demonstrated for cell migration 
and invasion (55). 
4.7 Rac1 and ERK1/2 pathways are involved in ROS production after FPRs 
stimulation in human normal foreskin fibroblasts 
In order to study the signaling pathways involved in FPRs mediated ROS generation in 
fibroblast cells, we focused our attention on the small GTPase Rac1 and on the ERK1/2 
pathway. 
Indeed, uPAR-controlled cell migration, which is allowed by uPAR interactions with 
FPRs and β1 integrins, involves specifically small Rac1 and Rho GTPases as signaling 
mediators (55). Moreover, one important effector of Rac1 activity is p67
phox
, which 
combines with other components of the NADPH oxidase system to generate a 
functional complex for producing ROS (62). 
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NADPH oxidase system-derived ROS can also activate other downstream signals, such 
as ERK 1/2 signalling pathways (63). Moreover, uPAR-dependent signaling pathways 
can also include PI3K and lead to the activation of ERK MAPKs (38). 
Thus, we analyzed the effects of FPRs stimulation with fMLF, WKYMVm peptide, and 
uPAR84–95 on Rac1 and ERK1/2 activation. All the stimuli, even with different kinetics, 
increased the levels of Rac1-GTP and p-ERK 1/2 (Fig. 10).  
Furthermore, we evaluated ROS levels after stimulation with the same agonists, in the 
absence and the in presence of an inhibitor of Rac-specific GEF (guanine nucleotide 
exchange factor) Trio and Tiam1 (NSC23766) and of a specific MEK 1/2 inhibitor 
(PD98059). BJ cells, which responded in a signiﬁcant manner to all the three stimuli (p 
˂ 0.05), were incapable to produce ROS in presence of NSC23766 and PD98059 (Fig. 
11). 
These data suggest that FPRs stimulation in normal fibroblasts could determine ROS 
production by activating Rac1 and ERK 1/2 dependent signals.  
 
4.8 FPRs induce ROS production through the upregulation and activation of 
NADPH oxidase-2 in human normal foreskin fibroblasts 
After establishing that FPRs activation induced ROS production through Rac1 and ERK 
1/2 signaling in the BJ cell line, we investigated whether ROS were generated by the 
NADPH oxidase-2 (Nox2 complex), being this NADPH oxidase isoform expressed in 
fibroblasts and mainly involved in SSc pathogenesis (64).  
Upon stimulation, activated GTP bound-Rac1 and/or Rac2 translocate to the plasma 
membrane and recruits p67
phox
 by binding to its N-terminal. The binding of p67
phox 
to 
Rac1/2-GTP is the limiting step in the assembly of the active NADPH oxidase complex 
(62).  
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To investigate whether FPRs stimulation could induce ROS production through 
upregulation and/or activation of the Nox2 complex, we evaluated, by Western Blot 
analysis, the expression levels of gp91
phox
 and p67
phox
 after stimulation with speciﬁc 
agonists of FPRs. As shown in Figure 12, BJ cells responded in a signiﬁcant manner to 
all the stimuli by upregulating the expression of both gp91
phox
 and p67
phox
. 
Rac1-GTP, but not Rac1-GDP, directly interacts with the N-terminal tetratricopeptide 
repeat (TPR) domain of p67
phox
 (29, 30), and serves as an “adaptor” by providing a 
stable platform for the interaction with the catalytic component gp91
phox
. 
To investigate whether FPRs stimulation could induce the interaction between Rac1-
GTP and p67
phox
,
 
a pull-down experiment was carried out in BJ cells, after stimulation 
with specific FPRs agonists. Active Rac1 (Rac1-GTP) was precipitated from cell lysates 
using the p21-binding domain (PBD) of its target, PAK1, bound to agarose beads. 
Rac1-GTP was eluted from beads and Western blot analysis of the precipitate with a 
polyclonal anti-p67
phox
 antibody revealed that FPRs stimulation increased interaction 
between Rac1-GTP and p67
phox
, thus allowing the assembly of the active Nox2 complex 
(Fig.13). 
After stimulation with specific FPRs agonists, no increased association between Rac1-
GTP and gp91
phox
 could be detected (not showed). 
Thus, our data demonstrated that FPRs/uPAR-mediated ROS generation in fibroblast 
cells is mediated by a direct binding of Rac1 to p67
phox
 that, in turn, interacts with the 
gp91
phox
 and p22
phox
 membrane subunits to generate the active Nox2 complex. 
 
4.9 FPRs mediated ROS production in human normal and SSc skin ﬁbroblasts  
In a next series of experiments, we also studied ROS release in primary cultures of 
normal and SSc ﬁbroblasts.  
36 
 
First, normal and SSc fibroblasts were tested, by flow cytometry analysis, for the ability 
to induce ROS generation. The basal level of fluorescence was determined in both cell 
types after loading with DCHF-DA. DCHF-DA-loaded normal and SSc fibroblasts 
didn’t show a different level of basal ROS production (Fig. 14A). After cell stimulation 
with H2O2 (1 mM), normal and SSc fibroblasts showed a similar, significant increase in 
ROS production (Fig. 14B).  
To prove that FPRs stimulation may have a role in ROS production also in primary 
fibroblasts, we evaluated ROS levels after 30 min of stimulation with the aminoterminal 
fragment of uPA (ATF-uPA), able to unmask the 
88
SRSRY
92
 sequence upon binding 
intact uPAR, the soluble uPAR84–95 peptide, and the FPRs agonist WKYMVm peptide 
and compared them with unstimulated cells. As shown in Figure 14C, normal primary 
skin ﬁbroblasts responded in a signiﬁcant manner to all the three stimuli (p ˂ 0.05), 
whereas in SSc ﬁbroblasts, only the WKYMVm peptide signiﬁcantly induced ROS 
generation. 
Thus, FPRs stimulation is effective in ROS production both in normal and SSc skin 
fibroblast; the response to ATF and uPAR84-95 is downregulated in SSc ﬁbroblasts as 
compared to normal. 
 
4.10 Therapeutic strategies to modulate FPRs/uPAR-mediated generation of oxidative 
stress by fibroblast cells  
We demonstrated FPRs involvement in ROS production and in the generation of 
oxidative stress, playing a key role in pathogenesis of fibrosis. 
Thus, we sought to investigate whether inhibition of the structural and functional 
interaction between FPRs and uPAR could affect ROS generation in BJ cell line. After 
stimulation with fMLF and the WKYMVm peptide, we treated cells with C37, a new 
37 
 
small molecule identified by our group through structure-based virtual screening,  and 
able to inhibit uPAR and FPRs cross-talk by targeting the 
88
SRSRY
92
 sequence of 
uPAR, in the hot-spot residue Arg
91
 (65). Figure 15A shows that the BJ cells, which 
responded in a signiﬁcant manner to both stimuli (p ˂ 0.05), were incapable to produce 
ROS in presence of C37. 
Many studies have shown that MAPKs are activated in response to fibrogenic agents 
and contribute to the formation and function of the myofibroblast, the critical cell type 
responsible for excessive scarring. Recently it has been demonstrated that the specific 
MEK inhibitor ARRY-142886 can both suppress the progression of fibrosis and reverse 
an animal model of lung fibrosis. Thus, MEK inhibition could be a valuable method to 
treat lung fibrosis (66). Moreover, we have demonstrated ERK 1/2 involvement in ROS 
generation induced by FPRs/ uPAR activation.  
Therefore, we investigated the effects of Selumetib, a highly selective MEK1 inhibitor 
currently approved for various anticancer therapies, on ROS release mediated by 
FPRs/uPAR activation. As shown in Figure 15B, Selumetinib completely abolished 
ROS production, in response to FPRs/uPAR specific agonists in BJ cell line. 
Results from these studies show that C37 and Selumetinib, through inhibition of FPRs-
mediated ROS generation, may lead to the development of novel antifibrotic therapeutic 
strategies. 
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5. CONCLUSIONS 
N-formyl peptide receptors (FPRs) are a family of pattern recognition receptors, 
regulating innate responses. FPRs, by interacting with several structurally diverse pro- 
and anti-inflammatory ligands, possess important regulatory effects in multiple 
pathophysiological conditions, including inflammation and cancer.  
Three variants of FPRs have been identified in humans: FPR1, FPR2, and FPR3. FPR1 
is activated by nanomolar concentrations of fMLF. FPR2 is a promiscuous receptor 
activated in response to high concentrations of fMLF, and to viral, bacterial, 
endogenous and synthetic peptides. Hp(2-20), uPAR84-95, and F2L are natural ligands of 
FPR3. The synthetic peptide WKYMVm is mainly a FPR2 and FPR3 agonist (18).  
Several functions of FPRs occur through the interaction with the urokinase-type 
plasminogen activator (uPA) receptor (uPAR). uPAR is formed by three homologous 
domains (DI, DII, DIII) anchored to the cell surface by a glycosyl-phosphatidylinositol 
(GPI) tail and is able to interact with integrins, FPRs and tyrosine kinase receptors, 
representing a main regulator of signal transduction pathways involved in wound repair, 
tumor progression and angiogenesis (55). A specific region of uPAR, corresponding to 
amino acids 88-92 (SRSRY), located in the flexible linker connecting uPAR domains 
DI and DII, is able to interact with FPRs, mediating uPA or fMLF-dependent cell 
migration. uPA or its aminoterminal fragment (ATF) can promote uPAR interaction 
with FPRs, by determining the exposure of the uPAR88-92 region, upon binding to the 
receptor. Further, uPA-mediated removal of DI results in the membrane expression of a 
truncated uPAR form, that can contain the chemotactic peptide able to interact with 
FPRs and to regulate their signal (DII-DIII-uPAR88-92) (37). 
Recently, to test the possibility of FPRs being involved in the pathogenesis of SSc, we 
have demonstrated that FPRs stimulation promotes α-smooth muscle actin expression in 
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primary cultures of normal dermal fibroblasts as well as motility, matrix deposition, and 
αvβ5 integrin expression, thus playing a role in fibrosis and in the fibroblast-to-
myofibroblast transition (57).  
In this thesis, we investigated whether FPRs stimulation and their cross-talk with uPAR 
could induce radical oxygen species (ROS) generation, thus playing a role in some 
ROS-mediated processes involved in SSc, such as tissue remodeling and fibrosis. 
We provided evidence, for the first time, that FPRs are expressed by human normal skin 
fibroblasts and that SSc fibroblasts overexpress these receptors both in vitro and in vivo. 
Furthermore, SSc fibroblasts showed increased membrane expression levels of DII-
DIII-uPAR88-92, expressing at the N-terminus the chemotactic sequence able to interact 
with overexpressed FPRs. Induction of the uPA pathway could be responsible for the 
increased expression of this cleaved uPAR form (67) even though our group could 
observe uPA increase only in localized SSc forms (47).  
In order to study the molecular mechanisms of FPRs-mediated ROS generation in 
fibroblast cells, we persued our studies on the BJ cell line. We demonstrated that FPRs 
stimulation induced ROS generation in normal fibroblasts by interacting with uPAR and 
forming a complex with integrins, as already demonstrated in epithelial cell migration 
and invasion (34). Our study also reported that FPRs/uPAR/1integrin cross-talk 
determines ROS production through Rac1 and ERKs activation in human skin 
fibroblasts.  
One important effector of Rac1 activity is p67
phox
, which combines with the NADPH 
oxidase system to generate a functional complex for producing ROS. Upon activation 
by GTP-Rac1, p67
phox
 translocates to the membrane where it associates with gp91
phox
. 
FPRs stimulation promoted gp91
phox
 and p67
phox
 expression as well as a direct 
interaction between GTP-Rac1 and p67
phox
.  
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We finally analyzed the effects of FPRs and uPAR stimulation on ROS production in 
normal and SSc fibroblasts from primary cultures. The intracellular ROS levels were 
determined after stimulation with ATF-uPA, able to bind only intact three domain 
uPAR, the soluble uPAR84-95 peptide, containing the uPAR-derived 
88
SRSRY
92
 
sequence, able to bind and activate FPRs, and the WKYMVm peptide, mostly acting on 
FPR2 and FPR3. Normal fibroblasts significantly responded to all the agonists, thus 
confirming that stimulation of FPRs and their crosstalk with uPAR could be involved in 
ROS production also in primary cells; on the contrary, only the WKYMVm peptide was 
a potent stimulus for SSc fibroblasts. As expected from histology, the absence of 
response to ATF-uPA in SSc fibroblast is not surprising; indeed, they do not express 
intact uPAR. The difference in the effect between uPAR84-95 and WKYMVm peptides 
could be due to the preferential involvement of FPR3 in the cross-talk with uPAR in 
SSc fibroblats. Indeed, FPR3 is exquisitely overexpressed in SSc fibroblasts, in respect 
to normal (Fig. 5) and the WKYMVm peptide is mostly a FPR2 and FPR3 agonists. 
In SSc fibroblasts, membrane overexpressed DII-DIII-uPAR88-92 could mostly interact 
with FPR1, and desensitize it toward uPAR84-95.  
However, FPRs, through the interaction with the uPA/uPAR system, are responsible for 
ROS production both in normal and SSc fibroblasts, making them a potential novel 
therapeutic target in the treatment of SSc. Indeed, the treatment with C37, able to inhibit 
the cross-talk between FPRs and uPAR, and the inhibition of the MAPK/ERK pathway 
with Selumetinib, inhibited ROS production, after stimulation of FPRs with specific 
ligands. 
In conclusions, the results of the present study show that the FPRs, through the 
interaction with the uPA/uPAR system, induce increased levels of ROS, thereby 
contributing to the scleroderma phenotype. In particular, the FPRs derived signals and 
41 
 
their cross-talk with uPAR appears to be important both in normal and SSc fibroblasts. 
Since, in SSc, early recognition and treatment of symptoms and life-threatening 
complications are crucial for patient clinical evolution, these observations can help in 
the development of novel therapeutic target in the treatment of early SSc. 
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6. FIGURES 
 
 
Jimenez, S. A. et al. Ann Intern Med, 2004. 
Figure 1. General overview of the pathogenesis of systemic sclerosis. The pathogenesis of SSc is 
extremely complex and remains incompletely understood. At present, no single unifying hypothesis 
explains all aspects of its pathogenesis. However, fundamental abnormalities in at least 3 types of cells 
are involved in the development of the clinical and pathologic manifestations of the disease: 1) 
fibroblasts; 2) endothelial cells; 3) immune cells, particularly T and B lymphocytes. The illustrations 
show examples of, from left to right, the ﬁbrotic process (biopsy of skin), microvascular alterations in 
pulmonary arterioles, autoantibodies detected by immunoﬂuorescence, and mononuclear inﬂammatory 
cell inﬁltrates in affected skin. 
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Gilbane, A. J. et al. Arthritis Res Ther, 2013. 
Figure 2. The cellular origins of pathogenic “activated” fibroblasts in scleroderma. Myofibroblast, 
the mesenchymal cell type most responsible for the excessive matrix production and deposition in tissue 
and vessel wall, found in ﬁbrotic disorders and ﬁbroproliferative vasculopathies. In ﬁbrotic diseases, 
myoﬁbroblasts may derive from at least three sources: 1) expansion and activation of resident tissue 
ﬁbroblasts; 2) transition of epithelial cells into mesenchymal cells, a process known as epithelial–
mesenchymal transition; and 3) tissue migration of bone marrow–derived circulating and ﬁbrocytes. SSc 
fibroblasts also promote a pro-fibrotic microenvironment, secreting growth factors, chemokines and 
cytokines that can in turn act on resident and infiltrating cells in an autocrine and  paracrine manner to 
expand the reservoir of pro-fibrotic fibroblasts present in SSc fibrotic lesions. 
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Figure 3. Agonists and antagonists of the N-formyl peptide receptor family. The family of N-formyl 
peptide receptors (FPRs) consists of three members defined: FPR1, FPR2 and FR3, that share a high 
degree of sequence homology. These receptors are capable of binding a very large number of ligands with 
different structural characteristics, including peptides formylated and not formylated, that, by acting as 
agonists, determine their activation. Upon agonist binding, FPRs are subjected to inactivation by 
desensitization. 
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Figure 4. Urokinase-type plasminogen activator (uPA) receptor (uPAR) forms and activities.  
A: plasma membrane uPAR is a GPI-anchored protein that binds with high-affinity the serine protease 
uPA, thus focusing its proteolytic activity at the cell surface. In addition, uPAR is and adhesion receptor 
and binds vitronectin (VN), a component of provisional ECM. Upon uPA and/or VN binding, uPAR 
interacts with the integrin family of adhesion receptors, thus regulating cell adhesion, proliferation and 
migration. Upon uPA binding or proteolytic cleavage, uPAR or its truncated form (DIIDIII-uPAR88-92) 
interacts with FPRs through the 
88
SRSRY
92
 sequence. uPAR/FPRs interaction is necessary for both uPAR 
and FPRs-mediated chemotaxis. 
B: phosphatidyl-inositol specific phospholipases can cleave the GPI anchor of uPAR thus releasing from 
the cell surface soluble uPAR forms that have been detected in human plasma and urine. Soluble intact 
uPAR (suPAR) retains all the activities of membrane-bound uPAR; the cleaved soluble form of uPAR 
(DIIDIII-suPAR88-92) is only able to bind FPRs through the 
88
SRSRY
92
 sequence. 
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Figure 5. FPRs expression in normal and SSc skin fibroblasts.  
A: Histological expression of FPRs in skin biopsies. (a–c) Histologic appearance of a localized 
scleroderma. (d) Histologic appearance of normal skin. (e–g) Immunostaining for FPR1 in a localized 
scleroderma. Overexpression of FPR1 was observed in ﬁbroblasts, endothelial cells, and lymphocytes. (h) 
Immunostaining for FPR1 in normal skin. Weak expression of FPR1 was observed in ﬁbroblasts, 
lymphocytes, and endothelial cells. (i–k) Immunostaining for FPR2 in a localized scleroderma. Only a 
minority of ﬁbroblasts resulted positive for FPR2. (l) Immunostaining for FPR2 in normal breast skin in 
normal skin. Only two ﬁbroblasts resulted positive for FPR2. (m–o) Immunostaining for FPR3 in a 
localized scleroderma. Most ﬁbroblasts show positivity for FPR3. Lymphocytes and endothelial cells 
were negative. (p) Immunostaining for FPR3. Some ﬁbroblasts showed positivity for FPR3. Lymphocytes 
and endothelial cells were negative.  
B: mRNA expression of FPRs in normal and SSc ﬁbroblasts with FPR1, FPR2, and FPR3-speciﬁc 
primers and GAPDH primers as loading control. Densitometric analysis of the FPR expression in normal 
(white columns) and SSc (gray columns) ﬁbroblasts show that SSc ﬁbroblasts overexpress FPR2 and 
FPR3 as compared with normal ﬁbroblasts.  
C: Western blot analysis of FPRs in normal and SSc ﬁbroblasts with anti–FPR1, anti–FPR2, and anti–
FPR3 speciﬁc Abs and then with α-tubulin Ab for loading control. Normalization with α-tubulin using 
densitometric analysis of the FPR protein levels shows a signiﬁcant increase of FPR1 and FPR3 in SSc 
ﬁbroblasts (gray columns) as compared with normal ﬁbroblasts (white columns). 
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Figure 6. uPAR expression in normal and SSc skin fibroblasts.  
A: (a-d) staining for R3 in localized scleroderma: fibroblasts, lymphocytes and endothelial cells were 
negative for R3 (a: original magnification, x25; b: original magnification, x50, c: original magnification, 
x100; d: original magnification, x200); (e-h) staining for IB in localized scleroderma: most fibroblasts, 
lymphocytes and endothelial cells were positive for IB (f: original magnification, x25; g: original 
magnification, x50, h: original magnification, x100; i: original magnification, x200); (i-l) staining for 
ADG in localized scleroderma: weak and focal expression of ADG was observed in fibroblasts, 
lymphocytes and endothelial cells [k: original magnification, x25; l: original magnification, x50, m: 
original magnification, x100; n original magnification, x200);  
B: (a-d) staining for IB on skin biopsy of a localized scleroderma previously evaluated for FPR1, 2 and 3 
antibodies expression: fibroblasts, lymphocytes and endothelial cells were positive for IB (a: original 
magnification, x25; b: original magnification, x50, c: original magnification, x100; d: original 
magnification, x200).  
C: Western blot analysis of DII-DIII-uPAR88–92 expression in normal and SSc skin ﬁbroblasts. Normal 
(lanes 1–3) and SSc (lanes 4–6) skin ﬁbroblasts were lysed in Triton X-100, and 50 µg total protein was 
analyzed by Western blot with an anti–uPAR84–95-speciﬁc Ab; three representative cases are shown. 
Densitometric analysis and normalization to a-tubulin of the DII-DIII-uPAR88–92 expression in normal 
(white column) and SSc ﬁbroblasts (gray column) are also shown. 
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Figure 7. Expression of FPRs in human normal ﬁbroblasts; uPAR expression and its direct 
interaction with FPR1 in normal foreskin fibroblast cells.  
A: Cytofluorimetric analysis of FPRs expression on human normal fibroblasts. Mean fluorescence 
intensity of FPR1(white column), FPR2(grey column), and FPR3 (black column) expression in BJ 
(human normal foreskin fibroblasts), HGF-1 (human normal gengival fibroblasts) and MRC-5 (human 
normal lung fibroblasts) cells over isotype control.  
B: Western blot analysis of uPAR expression in H460 cell line as a positive control (lane 1), BJ cell line 
at 1
st
 passage (lane 2) and 5
th
 passage (lane 3) in colture. H460 cell line and BJ cell line were lysed in 
Triton X-100, and 50 µg total protein was analyzed by Western blot with the R4 anti-uPAR mAb. and 
then with α-actin Ab for loading control.  
C: uPAR co-immunoprecipitation with FPR1. BJ cell lysates were immunoprecipitated with the R4 anti-
uPAR mAb (lane 2) or with nonimmune serum (lane 1). The immunoprecipitated samples were 
electrophoresed on 10% SDS-PAGE and analyzed by Western blot analysis with an anti-FPR1 Ab. 
Nonimmunoprecipitated cell lysates were subjected to Western blot analysis with the anti-FPR1 Ab (lane 
3) as a loading control. 
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Figure 8. Effects of fMLF ,WKYMVm peptide and uPAR84-95 on ROS production in the BJ cell line. 
Cells  were plated in a 96-well plate and treated with  DCHF-DA (5 μM) for 30 minutes at 37˚C in the 
dark. At the end of incubation, cells were washed with PBS and treated with medium alone ((black 
columns), or medium containing fMLF 10
-4 
M
 
(grey columns), WKYMVm 10
-8 
M
 
peptide
 
(white 
columns), uPAR84-95 10
-8 
M (light grey columns). ROS release was measured at a wavelength of 535 nm 
by a microplate reader (Tecan Trading AG, Switzerland) at 5, 15, 30 and 60 minutes. Results are 
expressed as mean ﬂuorescence intensity (IF) of DCHF-DA–loaded cells. DCHF-DA–loaded H2O2 
unstimulated cells and DCHF-DA–loaded H2O2 stimulated cells were examined in parallel, as controls, 
and are shown in insets. Values are the mean ± SEM of three experiments performed in triplicate. *p  
˂0.05; **p  ˂0.001. 
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Figure 9. Effects of the inhibition of the crosstalk between FPRs-uPAR-Integrins on ROS induction 
in the BJ cell line.  
A: Cells were plated in a 96-well plate and treated with DCHF-DA (5 μM) for 30 minutes at 37˚C in the 
dark. At the end of incubation, cells were washed with PBS and treated with medium alone or with fMLF 
10
-4
 M, in the absence (black columns) or in the presence of 5 µg/ml IB (light grey columns) and of 50 
µM P25 (dark grey columns). fMLF 10
-4
 M stimulated cells in the absence or in the presence of non 
immune immunoglobulins and a scrambled peptide, as a negative controls, are shown in the inset.  
B: Cells were plated in a 96-well plate and treated with DCHF-DA (5 μM) for 30 minutes at 37˚C in the 
dark. At the end of incubation, cells were washed with PBS and treated with medium alone or with 
WKYMVm 10
-8 
M, in the absence (black columns) or in the presence of 5 µg/ml IB (light grey columns) 
and of 50 µM P25 (dark grey columns). WKYMVm 10
-8 
M stimulated cells in the absence or in the 
presence of non immune immunoglobulins and scrambled peptide, used as a negative controls, are shown 
in the inset.  
ROS release was measured at a wavelength of 535 nm by microplate reader (Tecan Trading AG, 
Switzerland) at 5, 15, 30, and 60 minutes. Results are expressed as a percentage of mean ﬂuorescence 
intensity of stimulated DCHF-DA–loaded cells in respect to unstimulated DCHF-DA–loaded cells 
(considered as 100%). Values are the mean ± SEM of three experiments performed in triplicate. *p  
˂0.05; **p  ˂0.001. 
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Figure 10. FPRs-mediated Rac1 and ERK activation in the BJ cell line. 
A: Effects of fMLF, WKYMVm peptide and uPAR84-95 peptide on Rac1 activation. BJ cells, after 
incubation with fMLF (10
-4 
M) and with WKYMVm (10
-8 
M) for 5, 15, and 30 minutes, or with uPAR84-95 
peptide (10
-8 
M) at 5, 15, 30, and 60 minutes, at 37˚C in a humidiﬁed (5% CO2) incubator, were lysed and 
subjected to Rac1 activity assay using Pak-PBD-glutathione sepharose beads. Immunoprecipitates and the 
corresponding total lysates, as loading controls, were subjected to Western blot analysis with an anti Rac1 
specific antibody. 
B: Effects of fMLF, WKYMVm peptide and uPAR84-95 on Rac1 and ERK activation. BJ cells, after 
incubation with fMLF (10
-4 
M) and with WKYMVm (10
-8 
M) for 5, 15, and 30 minutes, or with uPAR84-95 
(10
-8 
M) at 5, 15, 30, and 60 minutes, at 37˚C in a humidiﬁed (5% CO2) incubator, were lysed and 
subjected to Western blot analysis with an anti phospho-ERK 1/2 (p-ERK) specific antibody and with an 
anti ERK-2 antibody, as a loading control. 
C: Densitometric analysis and normalization to total Rac1 of Rac1-GTP in BJ cells after treatment with 
medium alone, fMLF, WKYMVm peptide and uPAR84-95 peptide.  
D: Densitometric analysis and normalization to ERK 2 of p-ERK 1/2 in BJ cells after treatment with 
medium alone, fMLF, WKYMVm peptide and uPAR84-95. 
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Figure 11. Effects of Rac1 and ERK inhibition on FPRs-mediated ROS induction in the BJ cell line. 
Cells  were plated in a 96-well plate and treated with DCHF-DA (5 μM) for 30 minutes at 37˚C in the 
dark. At the end of incubation, cells were washed with PBS and treated with fMLF (10
-4 
M), WKYMVm 
peptide (10
-8 
M), or with uPAR84-95 peptide (10
-8 
M), in the absence (white column) or presence of 25 µM 
NSC23766 (black column) and 50 µM PD98059 (grey column). ROS release was measured at a 
wavelength of 535 nm by microplate reader (Tecan Trading AG, Switzerland) at 5, 15, 30 and 60 
minutes. minutes. The 5 minutes time point is shown  in the figure; similar results were obtained at 
increased time points. Results are expressed as a percentage of mean ﬂuorescence intensity of stimulated 
DCHF-DA–loaded cells in respect to unstimulated DCHF-DA–loaded cells (considered as 100%). Values 
are the mean ± SEM of three experiments performed in triplicate. *p ˂0.05; **p ˂0.001. 
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Figure 12. FPRs modulation of gp91
phox
 and p67
phox 
expression in the BJ cell line.  
A: Western blot analysis with anti-gp91
phox
, -p67
phox
 and -β-actin antibodies of  BJ cell lysates after 
incubation with fMLF (10
-4 
M) for 0, 5, 30, and 60 minutes.  
B: Western blot analysis with anti-gp91
phox
, -p67
phox
 and -β-actin antibodies of  BJ cell lysates after 
incubation with the WKYMVm peptide (10
-8 
M
 
) for 0, 5, 30, and 60 minutes.  
C: Western blot analysis with anti-gp91
phox
, -p67
phox
 and -β-actin antibodies of  BJ cell lysates after 
incubation with the uPAR84-95 (10
-8 
M) peptide for 0, 5, 30, and 60 minutes.  
D: Normalization  to β-actin using densitometric analysis of the gp91phox (light grey columns) and p67phox 
(dark grey column) 
 
protein levels.  
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Figure 13. FPRs-mediated Rac1 GTP-p67
phox
 interaction in the BJ cell line. 
A: BJ cell lysates were treated with GDP and GTPγS (Upstate) to generate Rac1-GDP and Rac1-GTP, 
respectively. Active Rac1 (Rac1-GTP) was precipitated from cell lysates using the p21-binding domain 
(PBD) of its target, PAK1, bound to agarose beads. Eluted samples were subjected to Western blot 
analysis with a polyclonal anti-p67
phox 
antibody. 
B: BJ cells, after incubation with medium alone (-), fMLF (10
-4
 M) and WKYMVm peptide (10
-8 
M) for 5 
minutes, or uPAR84-95 (10
-8 M) for 30 minutes at 37˚C in a humidiﬁed (5% CO2) incubator, were lysed 
and subjected to Rac1 activity assay. Active Rac1 (Rac1-GTP) was precipitated from cell lysates using 
the p21-binding domain (PBD) of its target, PAK1, bound to agarose beads. Eluted samples were 
subjected to Western blot analysis with a polyclonal anti-p67
phox 
antibody. 
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Figure 14. FPRs-mediated ROS production in human normal and SSc skin ﬁbroblasts. 
A: Intracellular oxidation in normal and SSc ﬁbroblasts in basal conditions. Normal (n = 10, white 
column) and SSc (n = 10, gray column) skin ﬁbroblasts were plated in a 6-well plate. Cells were untreated 
or treated with H2O2 (1 mM) for 30 min at 37˚C in the dark. At the end of incubation, cells were washed 
with PBS and loaded with DCHF-DA (5 µM) for 30 min; then, ROS release was measured by ﬂow 
cytometry at a wavelength of 520 nm (FL1). Results are expressed as percentage of increase of mean 
ﬂuorescence intensity DCHF-DA–loaded cells, as compared with DCHF-DA–unloaded cells.  
B: Intracellular oxidation in normal and SSc ﬁbroblasts in response to H2O2. Normal (n = 10, white 
column) and SSc (n = 10, gray column) skin ﬁbroblasts were plated in a 6-well plate. Cells were untreated 
or treated with H2O2 (1 mM) for 30 min at 37˚C in the dark. At the end of incubation, cells were washed 
with PBS and loaded with DCHF-DA (5 µM) for 30 min; then, ROS release was measured by ﬂow 
cytometry at a wavelength of 520 nm (FL1). Results are expressed as percentage of increase of mean 
ﬂuorescence intensity of H2O2-stimulated over H2O2-unstimulated cells.  
C: Effects of ATF-uPA, uPAR84–95, and WKYMVm on ROS production in normal and SSc skin 
ﬁbroblasts. Normal and SSc ﬁbroblasts were treated with medium alone (white column), ATF-uPA (10-9 
M) (light gray column), uPAR84–95 (10
-9
 M) (dark gray column), and WKYMVm peptide (10
-8
 M) (black 
column) for 30 min at 37˚C in a humidiﬁed 5% CO2 incubator. Cells were then washed twice, and 5 µM 
DCHF-DAwas added for 30 min in the dark at 37˚C. At the end of the incubation, cells were washed, 
trypsinized, and resuspended in PBS for ﬂow cytoﬂuorimetric analysis. A total of 104 events were 
acquired for each sample in all cytoﬂuorimetric analysis, and intracellular ROS formation was detected as 
a result of the oxidation of DCHF. DCHF-DA–loaded H2O2-unstimulated cells were considered the 100% 
of the dichloroﬂuorescein (DCF) ﬂuorescence. *p ˂ 0.05. 
 
56 
 
Figure 15. Effects of C37 and Selumetinib on FPRs-mediated ROS production in the BJ cell line.  
A: Cells were plated in a 96-well plate and treated with DCHF-DA (5 μM) for 30 minutes at 37˚C in the 
dark. At the end of incubation, cells were washed with PBS and treated with fMLF (10
-4 
M) and 
WKYMVm (10
-8 
M), in the absence (black column) or presence (grey column) of C37 (10 µM). ROS 
release was measured at a wavelength of 535 nm by microplate reader (Tecan Trading AG, Switzerland) 
at 5, 15, 30, and 60 minutes. Results are expressed as percentage of increase of mean ﬂuorescence 
intensity of stimulated DCHF-DA–loaded cells in respect to unstimulated DCHF-DA–loaded cells 
(considered as 100%).  
B: Cells were plated in a 96-well plate and treated with DCHF-DA (5 mM) for 30 minutes at 37˚C in the 
dark. At the end of incubation, cells were washed with PBS and treated with fMLF (10
-4 
M), WKYMVm 
(10
-8 
M), and 
 
uPAR84-95 (10
-8 
M) in the absence (black column) or presence (grey column) of Selumetinib 
(2.5 µM). ROS release was measured at a wavelength of 535 nm by microplate reader (Tecan Trading 
AG, Switzerland) at 5, 15, 30, and 60 minutes. Results are expressed as percentage of increase of mean 
ﬂuorescence intensity of stimulated DCHF-DA–loaded cells in respect to unstimulated DCHF-DA–
loaded cells (considered as 100%).  
Results are expressed as a percentage of mean ﬂuorescence intensity of stimulated DCHF-DA–loaded 
cells in respect to unstimulated DCHF-DA–loaded cells (considered as 100%). Values are the mean ± 
SEM of three experiments performed in triplicate. *p  ˂0.05; **p  ˂0.001.  
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